The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson’s disease

The MPTP Story

(2017) J. William Langston   Journal of Parkinsons Disease

The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling

(2016) Jorge L. Cueva Vargas et al.   NEUROBIOLOGY OF DISEASE

Disease-Modifying Drugs in Parkinson’s Disease

(2015) Ariane Park et al.   DRUGS

Parkinson’s disease and enhanced inflammatory response

(2015) Iva Stojkovska et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats

(2015) S. Sharma et al.   NEUROSCIENCE

Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis

(2015) Hanna M. Vesterinen et al.   PLoS One

Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine

(2014) Nazira El-Hage et al.   AIDS

Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease

(2014) Manuela Pilleri et al.   Expert Opinion On Drug Safety

The ongoing pursuit of neuroprotective therapies in Parkinson disease

(2014) Dilan Athauda et al.   Nature Reviews Neurology

Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets

(2014) F Ahmad et al.   ORAL DISEASES

Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease

(2014) Maciej Świątkiewicz et al.   Pharmacological Reports

Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease

(2014) Joanna Schwenkgrub et al.   Pharmacological Reports

The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinson's disease

(2014) Ilona Joniec-Maciejak et al.   Pharmacological Reports

Pretreatment with antiasthmatic drug ibudilast ameliorates Aβ1–42-induced memory impairment and neurotoxicity in mice

(2014) Hao Wang et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Initial management of Parkinson's disease

(2014) C. G. Goetz et al.   BMJ-British Medical Journal

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease

(2014) et al.   JAMA Neurology

Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders

(2013) Sorabh Sharma et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys

(2013) Zhenhua Ren et al.   Scientific Reports

Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies

(2012) Erwan Bezard et al.   MOVEMENT DISORDERS

The distribution of phosphodiesterase 2A in the rat brain

(2012) D.T. Stephenson et al.   NEUROSCIENCE

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

(2011) Thérèse Keravis et al.   BRITISH JOURNAL OF PHARMACOLOGY

PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: A key step in parkinsonism physiopathology

(2011) M. Giorgi et al.   NEUROBIOLOGY OF DISEASE

Fluoxetine protects neurons against microglial activation-mediated neurotoxicity

(2011) Feng Zhang et al.   PARKINSONISM & RELATED DISORDERS

Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update

(2010) Karen Nuytemans et al.   HUMAN MUTATION

Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues

(2010) Viktor Lakics et al.   NEUROPHARMACOLOGY

Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease

(2010) Carmela Giampà et al.   PLoS One

Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast

(2010) Y. Cho et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease

(2009) Katharine H Banner et al.   BRITISH JOURNAL OF PHARMACOLOGY

Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease

(2009) P Rolan et al.   EXPERT OPINION ON PHARMACOTHERAPY

The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson’s disease

(2009) Agnieszka Ciesielska et al.   INFLAMMATION RESEARCH

Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease

(2009) I. Kurkowska-Jastrzębska et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease

(2009) Peter Jenner   PARKINSONISM & RELATED DISORDERS

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

(2008) C. J. Schmidt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV

(2007) Lichuan Yang et al.   EXPERIMENTAL NEUROLOGY